Brand Information

Strength	Rate	Packing Style
400mg	284.48	10s f.c.tablets
400mg inf	335.77	250ml infusion

Drug Interaction:

Fluoroquinolones include the following :

Ciprofloxacin, Norfloxacin, Lomefloxacin, Ofloxacin, Pefloxacin, Enoxacin

Refer Ciprofloxacin

Drugs that prolong QT interval Class 1A or III arrhythmias

Neuroleptics Antidepressants NSAIDs

Erythromycin Antihistamines, cisapride, vincamine i.v. bepridil

Diphemanil, antacids, didanosine, sucralfate

Charcoal, multivitamins Mineral supplements,

Corticosteroids, hypkalaemic agents Anticoagulants

Indication:

Bronchitis

Acquired bacterial sinusitis

Community acquired pneumonia

LIST OF DRUGS DURING 2004

Sr.No- 230

Name of the Drug- Moxifloxacin Eye drops (0.5% Pharmacological Classification- For bacterial conjuctivitis

Date of Approval- 26-08-2004

Approved by U.S.FDA on 30-12-2004 (Ref- FDA approved List- 2004)

LIST OF DRUGS DURING 2006

Sr.No- 8

Name of the Drug- Moxifloxacin Eye ointment (5mg/gm) Pharmacological Classification- For ophthalmic use

Date of Approval- 06-02-2006

Approved by U.S.FDA on 30-12-2006 (Ref- FDA approved List- 2006

LIST OF DRUGS DURING 2007

Sr.No- 105

Name of the Drug- Moxifloxacin HCL (0.5%)+

Ketoprolac Tromethamine 0.5%

Ophthalmic solution

Pharmacological Classification- For reduction of post-operative inflammatory

conditions of the eyes

Date of Approval- 11-07-07

Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)

LIST OF DRUGS DURING 2007

Sr.No- 148

Name of the Drug- Moxifloxacin HCL (5mg) +

Prednisolone Acetate (10mg) per ml

(eye drops) Pharmacological Classification- For Inflammation after ocular surgery and

where a risk of bacterial ocular infection

exists

Date of Approval- 16-07-07

Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)

Approved by (DCI) Drug Controller GENERAL - India For Marketing

(Ref- IDMA Publication)

Name of Drug Indication Date of Approval

1.Moxifloxacin Anti bacterial 26-6-2001

2.Moxifloxacin Eye drops(0.5%) 26-082004

For Bactrerial Conjunctivitis

3.Moxifloxacin Eye Ointment (5mg/gm) 06-02-2006

For Ophthalmic Use

4.Moxifloxacin Hcl 0.5% 11-07-2007

+ Ketorolac Tromethane 0.5%

Ophthalmic solution

For reduction of post-operative inflammatory conditions of the eyes

5.Moxifloxacin Hcl 5mg 16-10-2007

+ Prednisolone Acetate 10mg/ml

Eye drops

For inflammation after ocular surgery where a risk of ocular

infection exists

6.Moxifloxacin hcl BP 0.5% w/v 05-01-2011

+ Brofemnac Sodium 0.09% w/v

eye drops

For the reduction of post-operative inflammation of the eye

Refer Ciprofloxacin

Adverse Reaction:

Abdominal pain, headche, dizziness,
g-i upset, QT prolongation

Taste pervertion, abnormal liver function tests,
Hepatitis, hepatic failure,

Seizures, pseudomembraneous coloitis,
tendon inflammation or rupture

Insomnia, nervousness, vertigo,
Monitor liver function and advice patients to report signs of hepatic disease

Heart failure in women and elderly
Photosensitivity reactions

Contra-Indications:

History of tension disorders
QT prolongation ,ncorrected hypokalemia
Cconcomittant admin. of class 1 eg quinidine, procainamide
Class III eg amiodarone, solatol
Anti-arrhythmiacs
Electrolyte disturbances,
Significant bradycardia,
Heart failure with reduced left ventricular ejection fraction

Pregnancy,lactation

Special precautions-
Risk of seizures
Seek specialIst opthalmologist advice if any effects on eye
Proarrhythmic conditions including badycardia
Acute MI and QT elongation, discontinue immediately
with signs of arrhhtmias and peform ECG
Avoid excess UV ex[posure
Risk of G6PD deficiency
Osteomylitis- advice patients to repport limb pain or inflammation
Risk of pseudomembranous colitis
Consider if patients have consistent diarrhoea
Hypersensitivity reactions may progress tofe threatening shock
Ddisconinue and initiate siutable treatment

Dosages/ Overdosage Etc:

Indication-

Bronchitis
Acquired bacterial sinusitis
Community acquired pneumonia

Dosage-

Can be taken wIth or without food

Bronchitis- 400mg daily for 5-10 days

Pharmacology/ Pharmacokinetics:

Pharmacology-
The bactericidal action of moxifloxacin results from inhibition of the topoisomerase I (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.
There is no cross resitence between moxifloxacin and other classes of antimicrobials.

Pharmacokinetics-
Moxofloxacin is well absorbed from the upper gastrointestinal GI tract and the absolute bioavailabilty reaches 82 to 89%
The plasm half life is ranges from 11.4 to 15.6 hrs depending on dose and indicates that once daily dosage regimen is suitable. Monofloxacin is eliminated via metabolic renal and biliary pathways.

Interaction with Food:

Can be taken wIth or without food

Pregnancy and lactation:

Use contraindicated. Observe caution

MOXICIP

Drug Interaction

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Pharmacology/ Pharmacokinetics

Interaction with Food

Pregnancy and lactation